KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Short-term Investments: 2010-2024

Historic Short-term Investments for Nektar Therapeutics (NKTR) over the last 15 years, with Dec 2024 value amounting to $211.0 million.

  • Nektar Therapeutics' Short-term Investments rose 6.90% to $229.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $229.2 million, marking a year-over-year increase of 6.90%. This contributed to the annual value of $211.0 million for FY2024, which is 21.38% down from last year.
  • As of FY2024, Nektar Therapeutics' Short-term Investments stood at $211.0 million, which was down 21.38% from $268.3 million recorded in FY2023.
  • Nektar Therapeutics' 5-year Short-term Investments high stood at $862.9 million for FY2020, and its period low was $211.0 million during FY2024.
  • For the 3-year period, Nektar Therapeutics' Short-term Investments averaged around $298.7 million, with its median value being $268.3 million (2023).
  • Data for Nektar Therapeutics' Short-term Investments shows a maximum YoY slumped of 41.20% (in 2022) over the last 5 years.
  • Over the past 5 years, Nektar Therapeutics' Short-term Investments (Yearly) stood at $862.9 million in 2020, then fell by 17.87% to $708.7 million in 2021, then tumbled by 41.20% to $416.8 million in 2022, then tumbled by 35.61% to $268.3 million in 2023, then decreased by 21.38% to $211.0 million in 2024.